Roche to invest $50 billion in United States over next five years
Roche on Tuesday said it will invest $50 billion in the United States over the next five years, in one of the biggest inward investment moves by companies dealing with President Donald Trump's tariffs policy.
Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe
The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after initial therapy.
Roche: Forget Tariffs And Focus On The Positives -- There Are Many
The Trump administration's proposed tariffs on pharmaceuticals have caused significant stock declines, but their implementation remains uncertain and may be aimed at achieving specific goals. Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a resilient investment. Roche's promising pipeline, particularly in obesity drugs, and its solid financial performance suggest long-term growth potential despite recent stock volatility.
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of the stock market. On Wednesday, Reuters reported that President Donald Trump is preparing to unveil a new series of tariffs on pharmaceutical imports.
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Roche Holdings AG RHHBY on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases.
South Korea needs political reform to attract investor interest: David Roche
David Roche, strategist at Quantum Strategy, and Victor Cha, president of the CSIS geopolitics and foreign policy department, discuss the possibility of constitutional reform in South Korea.
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG RHHBY on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple sclerosis (RMS) compared with the currently approved Ocrevus IV 600 mg dose.
Roche fails in bid to increase dose of MS drug Ocrevus
Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy benefit over the standard dose, a setback in a bid to further boost usage of the best-selling therapy.
The Zacks Analyst Blog Roche Holding, Comcast, Eaton Corp and National Presto Industries
Roche Holding, Comcast, Eaton Corp and National Presto Industries are included in this Analyst Blog.
Roche abandons global diversity targets on concern over U.S. executive orders
Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so.
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (VKTX 10.22%) and Roche Holdings (RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m.
